Education
About Us
Working with TipRanks
Follow Us
Puretech Health Plc (PRTC)
:PRTC
Top Page
PureTech Health
(NASDAQ:PRTC)
Rating:64Neutral
Price Target:
$19.00
▼(-1.30%Downside)
Positive Factors
Clinical Trial Results
PRTC announced positive results from the Ph 2b ELEVATE study of LYT-100, which is seen as supportive of a role in the IPF landscape as an improvement to standard of care anti-fibrotics.
Drug Development
LYT-100 demonstrates meaningfully improved efficacy with roughly comparable-to-improved safety compared to standard pirfenidone.
Regulatory Progress
The company plans to meet with the FDA to align on a Phase 3 study, indicating forward momentum in the development process.
Negative Factors
Drug Tolerability
Discontinuations in the LYT-100 arm were slightly higher than those for pirfenidone.
Investor Concerns
Investor interest in PRTC stock is limited by the expectation that promising assets will get spun out plus the low liquidity for the ADRs.
Stock Liquidity
PRTC stock continues to trade only modestly above cash levels as investors struggle with low liquidity for the ADRs and valuing the 'hub' of the 'hub-and-spoke' R&D model.
PureTech Health (PRTC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$470.51M
Dividend YieldN/A
Average Volume (3M)2.97K
Price to Earnings (P/E)9.3
Beta (1Y)0.81
Revenue Growth43.67%
EPS GrowthN/A
CountryUS
Employees80
SectorHealthcare
Sector Strength44
IndustryBiotechnology
Share Statistics
EPS (TTM)3.98
Shares Outstanding24,018,946
10 Day Avg. Volume2,466
30 Day Avg. Volume2,972
Financial Highlights & Ratios
PEG Ratio1.69
Price to Book (P/B)1.65
Price to Sales (P/S)0.00
P/FCF Ratio-4.93
Enterprise Value/Market Cap23.73
Enterprise Value/Revenue550.94
Enterprise Value/Gross Profit2.59K
Enterprise Value/Ebitda-59.54
Forecast
1Y Price Target
$46.00Price Target Upside138.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
PureTech Health Business Overview & Revenue Model
Company DescriptionPureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
How the Company Makes MoneyPureTech Health makes money primarily through the development and commercialization of its proprietary and partner-derived therapeutics. The company's revenue streams include milestone payments, royalties, and licensing fees from its collaborations and partnerships with larger pharmaceutical companies. These partnerships often involve co-development agreements that provide upfront payments and potential milestone-based earnings contingent on the achievement of specific clinical or regulatory milestones. Additionally, PureTech may generate revenue from the sale of equity interests in its founded entities when they achieve liquidity events such as public offerings or acquisitions. The company’s earnings are significantly influenced by its ability to innovate and bring new therapies to market, as well as its strategic alliances with industry leaders.
PureTech Health Earnings Call Summary
Earnings Call Date:Apr 30, 2025
(Q4-2024)
| % Change Since: 10.00%|
Next Earnings Date:Aug 27, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant achievements such as successful clinical trial results and FDA approval, alongside challenges like market valuation disconnect and funding requirements for future trials.Q4-2024 Updates
Positive Updates
Successful Phase 2b Trial of Deupirfenidone
PureTech announced unprecedented results from the successful Phase 2b trial of deupirfenidone for Idiopathic Pulmonary Fibrosis (IPF), demonstrating significant slowing of lung function decline over at least 26 weeks with a favorable tolerability profile. The trial showed a 50% greater effect size compared to placebo.
FDA Approval of COBENFY
COBENFY, invented at PureTech for the treatment of schizophrenia in adults, was approved by the FDA, marking a significant advance for patients and validation of PureTech's scientific foundation.
Strong Financial Position and Capital Efficiency
As of March 31, 2025, PureTech had approximately $339.1 million in cash, cash equivalents, and short-term investments, enabling the company to maintain financial discipline and strategic flexibility.
LYT-200 Clinical Progress
Strong Phase 1b trial data for LYT-200 in AML and solid tumors, with positive results including six complete responses in a highly pretreated population.
Negative Updates
Market Valuation Disconnect
Despite significant achievements and a robust pipeline, PureTech's market capitalization does not reflect its intrinsic value, leading to a focus on addressing this disconnect in 2025.
Funding Requirements for Phase 3 Trial
The potential Phase 3 trial for deupirfenidone in IPF may exceed PureTech's current cash balance, requiring exploration of external funding mechanisms such as spinouts and partnerships.
Operating Loss Despite Revenue Increase
Although operating loss decreased to $136.1 million from $146.2 million, the company still faces a significant operating loss despite an increase in revenue to $4.8 million.
Company Guidance
During the PureTech Health 2024 Year-End Financial Results Conference, key metrics and strategic priorities were discussed, emphasizing the company's financial and clinical achievements. As of March 31, 2025, PureTech reported a cash balance of approximately $339.1 million at the PureTech level, with a consolidated cash position of $339.5 million. The company raised $397.5 million in 2024, with over 88% from third-party investors, and generated $327.4 million from monetization events. PureTech returned $100 million to shareholders through a tender offer, showcasing robust financial execution. The guidance highlighted the successful Phase 2b trial of deupirfenidone for IPF, with plans to discuss a Phase 3 trial with the FDA by Q3 2025. PureTech's hub-and-spoke R&D model, known for its capital efficiency, was credited for enabling these developments. The company aims to address the value disconnect in its market valuation by exploring various strategic options, including potential transactions and additional capital return opportunities, to align its valuation with the intrinsic value of its assets and track record of execution.PureTech Health Financial Statement Overview
Summary
PureTech Health shows a mixed financial performance. The income statement reveals operational challenges despite a transition to positive net income in 2024. The balance sheet is robust with low leverage, but declining stockholders' equity raises concerns. Cash flow issues emphasize the need for better operational cash generation.Income Statement
PureTech Health has shown inconsistent revenue growth with a significant increase from 2023 to 2024. However, the company is operating at a loss, with negative EBIT and EBITDA margins indicating operational challenges. Although net profit margin turned positive in 2024, this has been volatile over the years.40
Negative
Balance Sheet
The company's balance sheet shows a strong equity ratio and low debt-to-equity ratio, suggesting good financial stability. However, the decrease in stockholders' equity over recent years could be a concern for long-term sustainability. Return on Equity turned positive in 2024, but this metric has been inconsistent historically.55
Neutral
Cash Flow
Cash flow analysis reveals negative free cash flow, although the company has managed a positive investing cash flow, likely from asset sales or investments. The operating cash flow to net income ratio is negative, suggesting that core operations are not generating sufficient cash.60
Neutral
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 4.32M | 3.33M | 2.09M | 9.98M | 8.34M | Gross Profit |
| 4.32M | -1.60M | -150.34M | -100.49M | 8.34M | EBIT |
| -136.09M | -146.20M | -197.81M | -150.28M | -119.53M | EBITDA |
| 37.38M | -11.63M | -52.19M | -46.95M | 62.69M | Net Income Common Stockholders |
| 53.51M | -65.70M | -37.06M | -62.71M | 4.57M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 367.31M | 327.14M | 350.10M | 465.71M | 403.88M | Total Assets |
| 602.63M | 693.97M | 702.65M | 946.01M | 989.99M | Total Debt |
| 22.36M | 25.34M | 46.87M | 52.02M | 76.62M | Net Debt |
| -258.28M | -165.74M | -102.99M | -413.68M | -327.26M | Total Liabilities |
| 194.70M | 235.74M | 155.06M | 361.86M | 336.45M | Stockholders Equity |
| 414.71M | 464.07M | 542.22M | 593.51M | 669.75M |
| Cash Flow | Free Cash Flow | |||
| -134.38M | -106.16M | -180.97M | -163.94M | -137.25M | Operating Cash Flow |
| -134.37M | -105.92M | -178.79M | -158.27M | -131.83M | Investing Cash Flow |
| 240.89M | 68.99M | -107.22M | 197.38M | 364.48M | Financing Cash Flow |
| -16.96M | 78.14M | -29.83M | 22.73M | 38.87M |
PureTech Health Technical Analysis
Positive
19.25
Price Trends
17.51
Positive
17.84
Positive
19.25
Negative
Market Momentum
0.44
Negative
60.62
Neutral
69.36
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRTC, the sentiment is Positive. The current price of 19.25 is above the 20-day moving average (MA) of 18.16, above the 50-day MA of 17.51, and below the 200-day MA of 19.25, indicating a neutral trend. The MACD of 0.44 indicates Negative momentum. The RSI at 60.62 is Neutral, neither overbought nor oversold. The STOCH value of 69.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRTC.
PureTech Health Peers Comparison
Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $620.22M | 14.62 | 20.50% | ― | 2333.50% | ― | |
69 Neutral | $633.76M | ― | -53.54% | ― | 12.04% | -31.81% | |
64 Neutral | $470.51M | 9.30 | 11.96% | ― | 43.67% | ― | |
55 Neutral | $620.11M | ― | -49.97% | ― | -14.16% | 25.80% | |
54 Neutral | $507.43M | ― | -204.78% | ― | 44.92% | -40.06% | |
54 Neutral | $5.38B | 3.40 | -45.06% | 3.28% | 16.75% | -0.02% | |
51 Neutral | $386.50M | ― | -48.98% | ― | -9.95% | 20.78% |
* Healthcare Sector Average
Performance Comparison
PRTC
PureTech Health
19.25
-10.55
-35.40%
EYPT
EyePoint Pharmaceuticals
8.81
-0.48
-5.17%
ZVRA
Zevra Therapeutics
9.37
4.46
90.84%
AUTL
Autolus Therapeutics
2.15
-2.38
-52.54%
STOK
Stoke Therapeutics
11.50
-6.02
-34.36%
ABSI
AbSci
3.01
-1.36
-31.12%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.